12,372 trials
Postherpetic Neuralgia · Complex Regional Pain Syndromes (CRPS) · Postoperative Pain
Primary: Time From the Initial Day of Application in Double-Blind Period to Withdrawal Because of Insufficient Analgesic Efficacy — NA; 45.0 Days — p=0.0003
Morbid Obesity · Postoperative Pain · Postoperative Bowel Function
Primary: Change From Baseline in Pain Scores (Visual Analogue Scale) — 1.4; 1.6; 1.6; 0.8 units on a scale
Low Back Pain
Primary: Percentage of Participants With Reduction in Pain Intensity — 57.65; 41.11 Percentage of Participants — p=0.0367
Insomnia · Attention Deficit Hyperactivity Disorder
Primary: Overall Incidence of Adverse Events — 212; 138; 10; 4 participants
Male Hypogonadism
Primary: Time to Target Eugonadal Range — 2.85 hours
Schizophrenia
Primary: Time to Exacerbation of Psychotic Symptoms/Impending Relapse — NA; 209 Days — p=<0.0001
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline at Week 24 — -0.18; -0.68 % of HbA1c — p=<0.0001
Bipolar Disorder
Primary: Change From Baseline in Young Mania Rating Scale (YMRS) Score at Week 4 — 26.2; 27.0; -13.8; -9.9 units on a scale — p=0.0005
Depression
Primary: Attrition (Number of Therapy Sessions Attended) — 15.4; 13.7 Number of Sessions — p=0.003
Multiple Myeloma · Plasma Cell Neoplasm
Primary: Progression-Free Survival — 78; 52 percentage of participants
Cardiovascular Diseases · Heart Diseases · Hypertension
Primary: Change in Diastolic Blood Pressure by Cuff 8-10 Weeks Minus Baseline — 3.44; -0.83 mm Hg — p=0.059
Pulmonary Arterial Hypertension
Primary: Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks — 382.94; 351.18 meters
Short Bowel Syndrome
Primary: A Graded Response Score in Parenteral Nutrition (PN) Reduction — 15; 19; 24; 0 participants — p=0.007
Macular Edema · Diabetic Mellitus · Retinal Disease
Primary: Number of Participants Who Experience a ≥10 Letter Improvement of Visual Acuity (VA) in Early Treatment Diabetic Retinopathy Study (ETDRS) Chart From Baseline at Week…
Rheumatoid Arthritis
Primary: Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24 — 15.0; 31.9; 44.8; 38.7 Percentage of participants — p=<0.0001